Dissacharide Patents (Class 514/53)
-
Patent number: 8815239Abstract: The present invention relates to compounds derived from sugars which reproduce the epitopes of Shigella flexneri serotypes 3a and X and to the use thereof for the preparation of vaccine compositions. More specifically, the subject matter of the present invention relates to novel glycoconjugated compounds comprising oligosaccharides or polysaccharides described hereinafter, to the method for synthesizing these oligosaccharides or polysaccharides and glycoconjugates, to derivatives of these oligosaccharides or polysaccharides, to compositions containing same, and also to the use of the glycoconjugates for vaccination purposes. Finally, the present invention relates to methods for diagnosing a Shigella flexneri infection using one or more oligosaccharides or polysaccharides or conjugates thereof.Type: GrantFiled: May 16, 2008Date of Patent: August 26, 2014Assignees: Institut Pasteur, Centre National de la Recherche Scientifique, Universite Paris DescartesInventors: Laurence Mulard, Julien Boutet, Catherine Guerreiro, Farida Nato, Philippe Sansonetti, Armelle Phalipon
-
Publication number: 20140234407Abstract: The method for increasing lactose tolerance in subjects exhibiting lactose intolerance symptoms implements a protocol where the subjects ingest a gradually increasing amount of lactose containing product over a six week period. At various points during the six week period the subject ingests the lactose containing product once a day and then twice a day. The lactose containing product can be in liquid form, such as for example, milk, and is preferably in a powder form which is taken either by ingesting capsules having the lactose powder or in a granular form mixed with water or other non-lactose containing liquid. At the end of the six week period, the subject's tolerance for lactose containing products is substantially increased, with the potential of eliminating the subject's lactose intolerant behavior indefinitely.Type: ApplicationFiled: October 24, 2013Publication date: August 21, 2014Applicant: RITTER PHARMACEUTICALS, INC.Inventor: Andrew Ritter
-
Publication number: 20140235570Abstract: The invention relates to a composition for the treatment of perianal disorders. In particular, the composition includes three components: a) an analgesic, b) a cryoprotective agent and c) a muscle relaxant.Type: ApplicationFiled: February 19, 2014Publication date: August 21, 2014Inventor: David Jonathan Hochman
-
Publication number: 20140228314Abstract: Disclosed is a method for preparation of a chitosan oligosaccharide composition capable of increasing a content of disaccharide in chitosan oligosaccharide with excellent effects of reducing HbAlc and blood glucose as well as excellent thermal stability. The method for preparation of a chitosan oligosaccharide composition includes: adding chitosan to distilled water to swell the chitosan; firstly treating the chitosan with a chitosanase to prevent the chitosan solution from becoming a state of being viscose, then, adding an organic acid to a mixed solution of the chitosan and chitosanase at a predetermined time interval bit by bit over several additions; allowing mutual reaction between the chitosan, chitosanase and organic acid; and inactivating the chitosanase to obtain the chitosan oligosaccharide composition. Further, a medicine and/or health supplement food which is effective in preventing and treating diabetes, including at least 40% of disaccharide without monosaccharide, is also disclosed.Type: ApplicationFiled: November 14, 2013Publication date: August 14, 2014Applicant: KUNPOONG BIO CO., LTDInventors: Chen-Gum OH, Young-In KWON, Jong-Wook LEE, Seong-Chul KIM
-
Patent number: 8802841Abstract: A 1,2-dideoxy-1,2-diamino oligosaccharide or polysaccharide in its free base, salt or metal-complex form as shown in General Formula 1 and derivative thereof is described. R1, R2 and R3 are each independently selected from the group consisting of H and a carbohydrate moiety, with the proviso that at least one of the groups R1, R2 or R3 is a carbohydrate moiety; R4 is selected from the group consisting of: H, optionally substituted C1-20-alkyl, optionally substituted heteroalkyl, optionally substituted C2-20-alkenyl, optionally substituted C2-20-alkynyl, optionally substituted C3-10-cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl.Type: GrantFiled: November 3, 2008Date of Patent: August 12, 2014Assignee: Glycom A/SInventors: Gyula Dekany, István Bajza, Marie Bøjstrup, Károly Ágoston, Lars Kröger, Ignacio Figueroa Pérez, Christoph H. Röhrig, Paulo Vital, Erzsébet Czinege
-
Patent number: 8802650Abstract: Disclosed are nutritional compositions including human milk oligosaccharides that can be administered to preterm infants, term infants, toddlers, and children for improving airway defense mechanisms.Type: GrantFiled: December 22, 2011Date of Patent: August 12, 2014Assignee: Abbott LaboratoriesInventors: Rachael Buck, Geralyn O. Duska-McEwen, Steven R. Davis
-
Publication number: 20140213530Abstract: This disclosure demonstrates that inhibition of Sirt5 can suppress malignant transformation of cells. Therefore, methods of treating cancer based on inhibition of Sirt5 are disclosed.Type: ApplicationFiled: September 7, 2012Publication date: July 31, 2014Applicant: CORNELL UNIVERSITYInventors: Hening Lin, Richard Cerione
-
Patent number: 8785416Abstract: The present invention relates to the use of a series of sulphated disaccharides for the preparation of a medicament for the treatment or prevention of a neurodegenerative and/or neurovascular disease, of a traumatic brain injury or of a traumatic spinal cord injury. The present invention also relates to the use of said sulphated disaccharides for the preparation of a neuroprotective medicament or of an antioxidant medicament. The neurodegenerative and/or neurovascular diseases are preferably: Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and stroke.Type: GrantFiled: December 22, 2010Date of Patent: July 22, 2014Assignees: Bioiberica, S.A., Universidad Autonoma de MadridInventors: Josep Verges Milano, Antonio Garcia Garcia, Ramon Ruhi Roura, Eulalia Montell Bonaventura, Manuela Garcia Lopez, Carlos Raul Alaez Verson, Josep Escaich Ferrer, Javier Egea Maiquez, Pilar Negredo Madrigal, Silvia Lorrio Gonzalez
-
NANOPARTICLE COATED WITH LIGAND INTRODUCED WITH LONG HYDROPHOBIC CHAIN AND METHOD FOR PREPARING SAME
Publication number: 20140199235Abstract: The present invention relates to a nanoparticle having a linker connected to a long alkane or alkene chain, and a method for preparing the nanoparticle. The alkyl chain of C10-30 introduced with a ligand of the present invention can be coated on a hydrophobic nanoparticle through a noncovalent bond, enabling easy introduction of various ligands to the nanoparticle, and the nanoparticle having various functional groups prepared using the method can be applied to fluorescent detection, MRI, raman spectroscopy, optical detection, PET, SPECT, or gamma image device, and the ligand of the visualization agents can be modified to be used for new vessels detection, cancer cell detection, immunocyte detection, hepatocyte detection, cell death detection, and gene detection.Type: ApplicationFiled: January 31, 2012Publication date: July 17, 2014Applicant: SNU R&DB FOUNDATIONInventors: Jae Min Jeong, Young Kyoung Lee, Dong Soo Lee, June-Key Chung, Myung Chul Lee -
Publication number: 20140200194Abstract: The invention provides a method for promoting osteogenesis, increasing bone mass or enhancing the rate of bone growth, which comprises administering to a subject an effective amount of Uraria, a part thereof or an extract thereof. Also provided are a method for treating and/or preventing osteoporosis and a method for providing neuroprotection, comprising administering to a subject an effective amount of Uraria, a part thereof or an extract thereof.Type: ApplicationFiled: January 16, 2013Publication date: July 17, 2014Applicant: TAIPEI MEDICAL UNIVERSITYInventor: Mei-Hsien Lee
-
Patent number: 8778907Abstract: A method of treating an adult patient in need of bowel evacuation via the administration of one or more doses of a bowel evacuant consisting of a total of from about 180 g to about 220 g of lactulose in a dosing regimen suitable to achieve bowel evacuation prior to a diagnostic, therapeutic or surgical procedure is disclosed.Type: GrantFiled: October 28, 2011Date of Patent: July 15, 2014Assignee: Cumberland PharmaceuticalsInventors: Leo Pavliv, Bryan Voss
-
Publication number: 20140187513Abstract: The present invention concerns a therapy aimed at language and/or social skills in infants through administration of components stimulating the development of a healthy intestinal flora.Type: ApplicationFiled: March 10, 2014Publication date: July 3, 2014Applicant: N.V. NutriciaInventors: Bernd STAHL, Jan KNOL
-
Publication number: 20140187512Abstract: A treatment for autism in which an effective amount of lactulose is administered in order to bind excess ammonia in the gastrointestinal tract, the bloodstream, and the nervous system in order to prevent or reverse ammonia poisoning caused by the administration of certain antibiotics. Lactulose molecules in the colon are fermented by certain bacteria. The fermentation process lowers the colonic pH, and ammonia, in the form of ammonium ions, is used by the bacteria for amino acid and protein synthesis. This lowers the serum ammonia levels and reduces neurotoxicity.Type: ApplicationFiled: November 22, 2013Publication date: July 3, 2014Applicant: Curemark LLCInventors: Joan M. Fallon, Richard Feltenstein
-
Patent number: 8765693Abstract: A method of inhibiting premature aging of human skin caused by exposure to infrared radiation comprising contacting the skin with a composition containing a therapeutically-effective amount of at least one protective compound chosen from baicalin, phloretin and neohesperidin dihydrochalcone, as well as combinations thereof.Type: GrantFiled: August 13, 2012Date of Patent: July 1, 2014Assignee: L'OrealInventors: Anthony Potin, Christian Oresajo, Nannan Chen, Donna McCann
-
Patent number: 8765694Abstract: The present invention is directed to methods for treating obesity, reducing excessive body weight, treating an obesity-related condition, treating unwanted localized fat deposits, and treating areas of cellulite. The method comprises the steps of first identifying a subject in need thereof, and administering to the subject an effective amount of rhamnolipids. A pharmaceutical composition comprising rhamnolipids can be applied by any accepted mode of administration including oral, intranasal, subcutaneous, percutaneous, intravenous, or intracutaneous administration.Type: GrantFiled: July 19, 2013Date of Patent: July 1, 2014Assignee: Rhamnopharma Inc.Inventor: Anton Leighton
-
Patent number: 8765665Abstract: A Factor VIII composition formulated without albumin, comprising the following formulation excipients in addition to Factor VIII: 4% to 10% of a bulking agent selected from the group consisting of mannitol, glycine and alanine; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent for maintaining a pH of approximately between 6 and 8. Alternatively, the formulation can comprise 2% to 6% hydroxyethyl starch; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent for maintaining a pH of approximately between 6 and 8.Type: GrantFiled: February 6, 2013Date of Patent: July 1, 2014Assignees: Baxter International Inc., University of ConnecticutInventors: Marc Besman, Erik Bjornson, Feroz Jameel, Ramesh Kashi, Michael Pikal, Serguei Tchessalov, John Carpenter
-
Patent number: 8759320Abstract: Process for the preparation of trivalent iron complexes with mono-, di- and polysaccharide sugars, consisting of the activation of the sugar by oxidation with nascent bromine generated in situ by reaction between an alkaline or alkaline earth bromine and an alkaline hypochlorite, the complexation of the activated sugar in solution with a ferric salt dissolved in an aqueous solution, the purification of the resulting solution through ultrafiltration and finally the stabilization of the trivalent iron-sugar complex by heating at a temperature between 60° C. and 100° C. for a period between 1 and 4 hours at a pH between 9.0 and 11.0.Type: GrantFiled: March 14, 2006Date of Patent: June 24, 2014Assignee: Biofer S.p.A.Inventors: Stefania Sacchi, Mauro Montorsi, Egidio Marchi
-
Patent number: 8759398Abstract: The present invention relates to oral pharmaceutical products which are useful for binding phosphorus in ingesta, and inhibiting absorption of phosphorus from the gastrointestinal tract of subjects. A method for binding phosphorus in ingesta and inhibiting its absorption from the gastrointestinal tract is also provided. The pharmaceutical products and methods of the present invention are particularly useful in the treatment of hyperphosphatemia of chronic uremia and reducing serum phosphorus levels in patients requiring such therapy.Type: GrantFiled: July 3, 2013Date of Patent: June 24, 2014Assignee: Biolink Life Sciences, Inc.Inventor: Deanna J. Nelson
-
Publication number: 20140170106Abstract: The methods and compositions disclosed herein are effective in the promoting the reattachment of delaminated cartilage to bone. The methods (and related compositions) comprise the removal of the acellular layer of the delaminated cartilage thereby exposing the underlying chondrocyte cells thereby allowing the promotion of the reattachment of the delaminated cartilage.Type: ApplicationFiled: November 8, 2013Publication date: June 19, 2014Inventors: Kelsey Jean Carvell, Ruth Cheng, Graham Smith, Drew Burdon
-
Publication number: 20140161903Abstract: The invention features topical formulations comprising an osmotically active agent and/or a vasoconstrictor and/or an astringent agent for the treatment and prevention of eyelid swelling, and methods of use thereof.Type: ApplicationFiled: February 12, 2014Publication date: June 12, 2014Applicant: ACIEX THERAPEUTICS, INC.Inventors: Matthew J. Chapin, Mark Barry Abelson, Keith Jeffrey Lane, Akimitsu Makino
-
Publication number: 20140162974Abstract: Compositions and methods for decreasing phosphorus, decreasing cFGF23, or increasing iFGF23 in a subject. Such compositions and methods can be useful for treatment of conditions, disorders, or diseases associated with phosphorus or FGF23 disregulation.Type: ApplicationFiled: March 5, 2013Publication date: June 12, 2014Applicant: LUITPOLD PHARMACEUTICALS, INC.Inventors: David B Bregman, Marc L Tokars
-
Publication number: 20140155346Abstract: The present invention relates to a topical composition, in particular a cosmetic and/or dermatological composition, to be used for preventing and/or treating stretch marks, including, in a physiologically acceptable medium, an effective amount of at least one synthetic polysulfated oligosaccharide having 1 to 4 glycose units, the salts thereof, and/or the derivatives thereof. The invention also relates to a cosmetic method, in particular for treating stretch marks, including at least one step of applying said composition to the skin.Type: ApplicationFiled: July 12, 2012Publication date: June 5, 2014Applicants: SOCIETE DE DEVELOPPEMENT ET DE RECHERCHE INDUSTRIELLE, LABORATOIRES URGOInventors: Laurent Apert, Marielle Bouschbacher
-
Patent number: 8741871Abstract: A trehalose compound having high immunopotentiating activity and low toxicity is represented by formula (1). (In the formula, X and X? each represents a phenyl, a naphthyl, R1—CHR1— (wherein R1 and R2 each represents a C7-C21 alkyl group or the like) or the like; and n and n? each independently represents an integer of 0-3). The compound exhibits a high activating effect on macrophages and neutrophils.Type: GrantFiled: October 27, 2009Date of Patent: June 3, 2014Assignee: Glytech, Inc.Inventors: Mugio Nishizawa, Hiroshi Imagawa, Hirofumi Yamamoto, Jun Sakurai, Masataka Oda, Reiko Nishizawa
-
Patent number: 8741872Abstract: Kits and compositions for producing an alginate gel are disclosed. The kits and compositions comprise soluble alginate and insoluble alginate/gelling ion particles. Methods for dispensing a self-gelling alginate dispersion are disclosed. The methods comprise forming a dispersion of insoluble alginate/gelling ion particles in a solution containing soluble alginate, and dispensing the dispersion whereby the dispersion forms an alginate gel matrix. The methods may include dispensing the dispersion into the body of an individual. An alginate gel having a thickness of greater than 5 mm and a homogenous alginate matrix network and homogenous alginate gels free of one or more of: sulfates citrates, phosphates, lactates, EDTA or lipids are disclosed. Implantable devices comprising a homogenous alginate gel coating are disclosed. Methods of improving the viability of pancreatic islets, or other cellular aggregates or tissue, following isolation and during storage and transport are disclosed.Type: GrantFiled: June 28, 2013Date of Patent: June 3, 2014Assignee: FMC Biopolymer ASInventors: Jan Egil Melvik, Michael Dornish, Edvar Onsoyen, Astrid B. Berge, Terje Svendsen
-
Publication number: 20140142061Abstract: The present invention relates to the use of a galactooligosaccharide composition for preventing or reducing the risk of developing metabolic syndrome.Type: ApplicationFiled: June 20, 2012Publication date: May 22, 2014Inventors: Georgios Tzortzis, Jelena Vulevic
-
Patent number: 8728465Abstract: Compositions comprising dendritic cells pulsed with tumor lysate and at least one toll-like receptor (TLR) ligand which may be used for eliciting a specific immune response in a mammal in need thereof for treating diseases including a tumor are disclosed. Also disclose are methods of activating dendritic cells, comprising providing at least one toll-like receptor (TLR) ligand; and pulsing a dendentic cell with the at least one TLR ligand. A method further comprises pulsing the dendritic cell with a tumor lysate.Type: GrantFiled: June 17, 2009Date of Patent: May 20, 2014Assignee: Cedars-Sinai Medical CenterInventors: Keith L. Black, Dwain Morris-Irvin, Moshe Arditi
-
Patent number: 8728504Abstract: A process for solubilizing hydrophobic active ingredients in aqueous medium, which comprises using, as an assistant, at least one hyperbranched polymer (A) which is obtainable by reacting at least one hyperbranched polymeric compound having at least one primary or secondary amino group per molecule (a), selected from (a1) hyperbranched polyamides and (a2) hyperbranched polyureas, with (b) at least one mono-, di- or oligosaccharide.Type: GrantFiled: February 4, 2011Date of Patent: May 20, 2014Assignee: BASF SEInventors: Bernd Bruchmann, Holger Türk, Daniel Schönfelder, Monika Haberecht, Dietmar Appelhans, Victor Boyko
-
Patent number: 8728535Abstract: In one embodiment of the present invention, a pharmaceutically-acceptable single-dosage formulation consists essentially of about 500 mg of vitamin C; about 400 IUs of vitamin D3; about 125 IUs of vitamin E; about 25 mg of vitamin B1; about 3.4 mg of vitamin B2; about 35 mg of niacin; about 35 mg of vitamin B6; about 1.25 mg of folic acid; about 70 mcg of vitamin B12; about 5 mg of pantothenic acid; about 75 mcg of biotin; about 35 mg of magnesium; about 35 mg of zinc; about 1 mg of copper; about 125 mcg of selenium; about 150 mcg of chromium; about 10 mg of alpha lipoic acid; about 35 mg of co-enzyme Q-10; about 400 mcg of lutein; about 125 mcg of lycopene; and at least one or more excipients.Type: GrantFiled: June 19, 2012Date of Patent: May 20, 2014Assignee: Vertical Pharmaceuticals, LLCInventors: Steven A. Squashic, Kevin M. Hudy, David C. Purdy
-
Publication number: 20140135281Abstract: The present invention relates to methods and compositions comprising cyromazine for the control of bee mites and for the reduction of bee mite infestations, such as the control and reduction of infestations of parasitic bee mites, such as Varroa destructor in bee, preferably honey bee, colonies, and to the treatment of varroatosis in bees.Type: ApplicationFiled: May 14, 2012Publication date: May 15, 2014Applicant: SYNGENTA PARTICIPATIONS AGInventor: Andre Fougeroux
-
Publication number: 20140135282Abstract: The present application provides a pharmaceutical composition for use in inhibiting recurrence, aggravation or metastasis of liver cancer, in which the pharmaceutical composition comprises at least one compound having a structure of formula (I) and a pharmaceutically acceptable vehicle.Type: ApplicationFiled: June 9, 2011Publication date: May 15, 2014Applicant: MEDIGEN BIOTECHNOLOGY CORPInventors: Stanley Chang, Kuan-Lang Lai
-
Patent number: 8722064Abstract: Compounds, particularly, glucopyranosyl lipid adjuvant (GLA) compounds, having the following structure (I) are provided: or a pharmaceutically acceptable salt thereof, wherein L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, Y1, Y2, Y3, Y4, R1, R2, R3, R4, R5, R6, are as defined herein. Pharmaceutical compositions, vaccine compositions, and related methods for inducing or enhancing immune responses, are also provided.Type: GrantFiled: June 4, 2010Date of Patent: May 13, 2014Assignee: Infectious Disease Research InstituteInventors: Steven G. Reed, Darrick Carter
-
Publication number: 20140121179Abstract: The present invention relates to a compound of the general formula (I): The compound of formula (I) is suitable for treating pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a mammal. Furthermore the present invention concerns a method of monitoring development or progression of pulmonary fibrosis in a human subject, a method of monitoring or predicting exacerbation of symptoms in a human subject with pulmonary fibrosis as well as a method for treatment of pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a human subject having a galectin-3 level indicative of pulmonary fibrosis or exacerbation of symptoms.Type: ApplicationFiled: March 15, 2013Publication date: May 1, 2014Inventors: Neil Henderson, Tariq Sethi, Alison Mackinnon, Hakon Leffler, Ulf Nilsson
-
Publication number: 20140121180Abstract: The invention relates to a sucrose octasulfate of magnesium, having general formula I, the preparation method thereof and the use of same in the pharmaceutical and/or cosmetic field, wherein 0?n?4, n is an integer and Y represents OH, Cl, Br, I, NO3, C6H5O7, CH3CO2, CF3CO2 or —OCH3.Type: ApplicationFiled: May 31, 2012Publication date: May 1, 2014Applicant: PIERRE FABRE DERMO-COSMETIQUEInventors: Séverine Jeulin, Hélène Hernandez-Pigeon, Luc Aguilar
-
Patent number: 8703722Abstract: The present invention relates to blood group A/B/H determinant on Type 1 Core glycosphingolipids chains as recognition point for the FedF protein of F18-fimbriated Enterotoxigenic and verotoxinogenic Escherichia coli and the use of compounds comprising such determinants for the treatment of F18+ E. coli infections in pigs and in screening methods.Type: GrantFiled: September 30, 2009Date of Patent: April 22, 2014Assignee: Universiteit GentInventors: Annelies Coddens, Eric Cox, Susann Eva Teneberg
-
Publication number: 20140107012Abstract: A trehalulose-containing composition, its preparation and use.Type: ApplicationFiled: November 20, 2013Publication date: April 17, 2014Applicant: SÜDZUCKER AKTIENGESELLSCHAFT MANNHEIM/OCHSENFURTInventors: Wolfgang WACH, Thomas ROSE, Michael KLINGEBERG, Siegfried PETERS, Tillmann DÖRR, Stephan THEIS, Jörg KOWALCZYK, Stephan HAUSMANNS
-
Publication number: 20140100189Abstract: A carbohydrate mixture for dietetic foods and pharmaceuticals is provided. The carbohydrate mixture comprises two different, substantially soluble carbohydrate components A and B, which remain undigested in the gastrointestinal tract and enter the large intestine without being resorbed. Carbohydrate component A may comprise at least one monosaccharide or of at least one oligosaccharide (disaccharide to hexasaccharide) or a mixture of two or more of these saccharides. Carbohydrate component B may comprise a polysaccharide (from heptasaccharide onwards) or a mixture of two or more polysaccharides. Carbohydrate component A=5 to 95 wt-% and carbohydrate component B=5 to 95 wt-% of the sum of the carbohydrate components A+B (=100 wt-%), and at least 80 wt-% of the carbohydrates/saccharides of both carbohydrate components have a prebiotic effect. The carbohydrate mixtures have not only a nutritive effect but they also stimulate health-promoting microorganisms present in the natural flora of the large intestine.Type: ApplicationFiled: October 7, 2013Publication date: April 10, 2014Applicant: N.V. NutriciaInventors: Gunther SAWATZKI, Bernd Stahl
-
Publication number: 20140099381Abstract: The present invention generally relates to treatment of iron-related conditions with iron carbohydrate complexes. One aspect of the invention is a method of treatment of iron-related conditions with a single unit dosage of at least about 0.6 grams of elemental iron via an iron carbohydrate complex. The method generally employs iron carbohydrate complexes with nearly neutral pH, physiological osmolarity, and stable and non-immunogenic carbohydrate components so as to rapidly administer high single unit doses of iron intravenously to patients in need thereof.Type: ApplicationFiled: December 9, 2013Publication date: April 10, 2014Applicant: Luitpold Pharmaceuticals, Inc.Inventors: Mary Jane Helenek, Marc L. Tokars, Richard P. Lawrence
-
Patent number: 8691796Abstract: A pharmaceutical composition for inhibiting inflammation, comprising (a) hyaluronic acid, (b) a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, and (c) a pharmaceutically acceptable carrier, is provided. Also provided is a method for inhibiting inflammation in a mammal, comprising administrating to the mammal an effective amount of a composition comprising (a) hyaluronic acid and (b) an HMG-CoA reductase inhibitor.Type: GrantFiled: February 10, 2011Date of Patent: April 8, 2014Assignee: China Medical UniversityInventors: Feng-Huei Lin, Teng-Le Huang, Horng-Chaung Hsu
-
Patent number: 8691776Abstract: A process for preparing parenteral iron-saccharidic complexes, and the complexes produced, comprising: (1) providing an aqueous solution or dispersion including (i) Fe(III) and (OH)? ions and (ii) at least one saccharide, to form a reaction mixture, where the molar ratio of (i):(ii) is about 30:1 to about 1:30; and the mixture temperature and pH are at or above the complex assembly point (CAP); and (2) maintaining temperature and pH at or above the CAP for a time sufficient to form an iron-saccharidic complex having a molecular weight of about 25,000 Daltons or more. Control of the temperature and pH efficiently produces a high molecular weight complex. The complex can be separated by precipitation, dialysis and/or column fractionation and, if desired, dried, e.g., lyophilized or spray dried. The process can controllably synthesize complexes of varying molecular weight and/or chemical composition, particularly sodium ferric gluconate and ferric hydroxide-sucrose.Type: GrantFiled: May 16, 2011Date of Patent: April 8, 2014Assignee: Chromaceutical Advanced Technologies,Inc.Inventors: Robert A. Beck, Robert A. Mateer, Jr., John Kowalski
-
Patent number: 8685942Abstract: A composition of matter comprising sophorolipids as antimicrobial agents, antifungal agents, biopesticides, for uses as drugs to treat HIV, septic shock, cancer, asthma, dermatological conditions, as spermicidal agents, as anti-inflammatory drugs, as ingredients in cosmetics and building blocks for monomers and polymers and self-assembled templates for further chemical elaboration.Type: GrantFiled: April 5, 2011Date of Patent: April 1, 2014Inventors: Richard A. Gross, Mark H. Schofield
-
Patent number: 8685439Abstract: The invention features novel topical ophthalmic formulations comprising an osmotically active agent and a vasoconstrictor. Suitable osmotically active agents for use in the ophthalmic formulations of the invention include, without limitation, sodium chloride, dextrose, glycerine, sucrose, mannitol, and sorbitol; suitable vasoconstritors include, without limitation, naphazoline and oxymetazoline. Also provided are methods of using the ophthalmic formulations of the invention for the treatment and prevention of eyelid swelling by administering the ophthalmic formulations of the invention to the eye surface of a subject in need thereof.Type: GrantFiled: April 26, 2007Date of Patent: April 1, 2014Assignee: Aciex Therapeutics, Inc.Inventors: Matthew Jonathan Chapin, Mark Barry Abelson, Keith Jeffrey Lane, Akimitsu Makino
-
Publication number: 20140088036Abstract: The present invention provides, among other things, phosphorylated and pyrophosphate derivatives of mono-, di- and oligosaccharides, as well as structural derivatives of these compounds. These compounds have a variety of uses including for pharmaceutical applications. Also provided are methods of use in the treatment of disease, including diseases related to oxygen delivery.Type: ApplicationFiled: September 30, 2011Publication date: March 27, 2014Applicants: UNIVERSITE DE STRASBOURG, NORMOXYS, INC.Inventors: Jean Marie Lehn, Yves Claude Nicolau, Rajamalleswaramma Jogireddy, Adam H. Brockman, John Hey, Yongxin Yu
-
Patent number: 8673877Abstract: A treatment for autism in which an effective amount of lactulose is administered in order to bind excess ammonia in the gastrointestinal tract, the bloodstream, and the nervous system in order to prevent or reverse ammonia poisoning caused by the administration of certain antibiotics. Lactulose molecules in the colon are fermented by certain bacteria. The fermentation process lowers the colonic pH, and ammonia, in the form of ammonium ions, is used by the bacteria for amino acid and protein synthesis. This lowers the serum ammonia levels and reduces neurotoxicity.Type: GrantFiled: August 8, 2011Date of Patent: March 18, 2014Assignee: Curemark, LLCInventors: Joan M. Fallon, Richard Feltenstein
-
Publication number: 20140065062Abstract: The present invention relates to a novel family of alkylated halogenated di- and trisaccharides which exhibit pharmaceutical efficacy in the areas of permeation enhancers, anti-microbial effects, anti-fugal effects, facilitation of diagnostic procedures. The invention further includes methods of treatment and diagnostic kits.Type: ApplicationFiled: November 4, 2013Publication date: March 6, 2014Inventor: Bahram Memarzadeh
-
Patent number: 8664372Abstract: In preparing a glycoside compound from (a) a furanose compound or pyranose compound, and (b) an alcohol compound, a process for preparing a glycoside compound in which glycosidic bond locates selectively trans form relative to C-2 hydroxyl group, the process comprising using a furanose compound wherein the hydroxyl at the 2-position may have a substituent protected with a group A, or a pyranose compound which may have a substituent wherein R2 and R3 are the same or different and are each alkyl having 1 to 4 carbon atoms or aryl having or not having a substituent, or R2 and R3 are combined to form alkylene having 2 to 4 carbon atoms (the alkylene may be substituted with alkyl having 1 to 4 carbon atoms, or may have intervening phenylene), and m and n are each an integer of 0 or 1.Type: GrantFiled: May 22, 2012Date of Patent: March 4, 2014Assignee: Glytech, Inc.Inventor: Shigeru Yamago
-
Patent number: 8664196Abstract: The present invention provides a shark-like chondroitin sulphate and a process for the preparation thereof. In particular, the present invention relates to a shark-like chondroitin sulphate, having a very low amount of 4-sulphate, a high charge density and a biological activity comparable to natural chondroitin sulphates. The invention also relates to a process for the preparation of said shark-like chondroitin sulphate affording substantially higher productivities and better reproducibility of product quality. The shark-like chondroitin sulphate of the invention shows a high molecular mass and its in vitro biological and anti-inflammatory effectiveness has been shown to be comparable to that of natural products making this polysaccharide potentially useful as a drug in pharmaceutical preparations and nutraceuticals.Type: GrantFiled: May 20, 2011Date of Patent: March 4, 2014Assignee: Gnosis S.p.A.Inventors: Ermanno Valoti, Niccolò Miraglia, Davide Bianchi, Marco Valetti, Paola Bazza
-
Patent number: 8658179Abstract: The present invention is directed to ligand/receptor and antigen/antibody specificity exchangers comprising a saccharide or glycoconjugate. Methods of making these specificity exchangers and methods of using said specificity exchangers to treat or prevent human disease are described herein.Type: GrantFiled: October 17, 2012Date of Patent: February 25, 2014Assignee: Chrontech Pharma ABInventors: Matti Sällberg, Anders Vahlne, Maria Perdomo
-
Patent number: 8653049Abstract: The invention provides a compound (which can act as an adjuvant) of Formula I or Formula (II), wherein R1 R4 R5 R6 and R7 are each independently selected from hydrogen, acetyl, hydrocarbyl, a lipid moiety and a lipid acyl moiety; R2 is a hydroxyl, a hydrocarbyl, a lipid moiety, a lipid acyl moiety; or an amino hydrocarbyl group optionally substituted with a hydrocarbyl, a lipid moiety or a lipid acyl moiety; R3 and R8 are each independently selected from acetyl, a hydrocarbyl, a lipid moiety and a lipid acyl moiety; X is a peptide chain; The above normuramylglycopeptide compounds can be located in liposomes and micelles and can function as immunomodulators, along with a desired antigen (or DNA encloding the antigen), in (e.g. DNA) vaccines.Type: GrantFiled: March 17, 2009Date of Patent: February 18, 2014Assignees: Imuthes Limited, Institute of Organic Chemistry and Biochemistry AV CR, V.V.I., Vyzkumny USTAV Veterinarniho Lekarstvi, V.V.I.Inventors: Karsten Hipler, Andrew Miller, Jaroslav Turanek, Miroslav Ledvina
-
Patent number: 8648055Abstract: A method for neutralizing or inactivating a virus, and neutralizing or inactivating HIV using sophorolipids having antiviral properties produced by synthesizing the sophorolipid by fermentation of Candida bombicola in a fermentation media to form a natural mixture of lactonic sophorolipids compounds and non-lactonic sophorolipids compounds and utilizing the natural mixture as an antiviral agent, and/or separating the lactonic sophorolipids from the natural mixture to form a lactonic fraction and mixing all remaining fractions to form a non-lactonic fraction and utilizing the lactonic fraction and/or the non-lactonic fraction as an antiviral agent, and sophorolipid compounds for use as antiviral agents.Type: GrantFiled: March 5, 2012Date of Patent: February 11, 2014Assignee: SyntheZyme, LLCInventors: Richard A Gross, Vishal Shah, Gustavo Doncel
-
Patent number: 8642562Abstract: The present invention relates to compositions and methods of their production and use, including use in increasing de-N-acetyl sialic acid antigen of a mammalian cell and methods that exploit the increase in deNAc sialic acid antigen on such cells.Type: GrantFiled: December 12, 2011Date of Patent: February 4, 2014Assignee: Children's Hospital & Research Center OaklandInventors: Gregory R. Moe, Brent T. Hagen